The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial | Zendy

Sun Huh | Zendy; Jung Won Shin | Zendy; JungIm Na | Zendy; ChangHun Huh | Zendy; Sang Woong Youn | Zendy; KyoungChan Park | Zendy

Open Access

The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial

Author(s) -

Sun Huh,

Jung Won Shin,

JungIm Na,

ChangHun Huh,

Sang Woong Youn,

KyoungChan Park

Publication year - 2010

Publication title -

annals of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.385

H-Index - 37

eISSN - 2005-3894

pISSN - 1013-9087

DOI - 10.5021/ad.2010.22.1.21

Subject(s) - melasma , medicine , dermatology , randomized controlled trial , adverse effect , hyperpigmentation , surgery

Melasma is a common acquired symmetrical hypermelanosis that occurs on sun-exposed areas, and it is frequently observed among women. Various treatment modalities have been tried, but none are completely satisfactory. 4-n-butylresorcinol, which is a resorcinol derivative that has an inhibitory effect on both tyrosinase and tyrosinase-related protein-1, was introduced in 1995 and it has received increasing attention as a new hypopigmenting agent. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research